Opthea (OPT) Competitors

Opthea (NASDAQ:OPT) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, community ranking, risk and valuation.

Which has more volatility & risk, OPT or HRMY?

Opthea has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Does the MarketBeat Community believe in OPT or HRMY?

Harmony Biosciences received 45 more outperform votes than Opthea when rated by MarketBeat users. Likewise, 70.33% of users gave Harmony Biosciences an outperform vote while only 48.72% of users gave Opthea an outperform vote.

Company	Underperform	Outperform
Opthea	Outperform Votes 19 48.72%	Underperform Votes 20 51.28%
Harmony Biosciences	Outperform Votes 64 70.33%	Underperform Votes 27 29.67%

Is OPT or HRMY more profitable?

Harmony Biosciences has a net margin of 17.98% compared to Opthea's net margin of 0.00%. Harmony Biosciences' return on equity of 23.16% beat Opthea's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opthea	N/A	N/A	N/A
Harmony Biosciences	17.98%	23.16%	14.24%

Do institutionals and insiders hold more shares of OPT or HRMY?

56.0% of Opthea shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 3.2% of Opthea shares are held by company insiders. Comparatively, 30.8% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the media favor OPT or HRMY?

In the previous week, Opthea had 29 more articles in the media than Harmony Biosciences. MarketBeat recorded 43 mentions for Opthea and 14 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 0.91 beat Opthea's score of -0.38 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opthea	2 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	10 Negative mention(s)	5 Very Negative mention(s)	Neutral
Harmony Biosciences	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend OPT or HRMY?

Opthea currently has a consensus price target of $1.33, indicating a potential downside of 60.90%. Harmony Biosciences has a consensus price target of $53.33, indicating a potential upside of 60.69%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Harmony Biosciences is more favorable than Opthea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opthea	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Harmony Biosciences	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better valuation & earnings, OPT or HRMY?

Harmony Biosciences has higher revenue and earnings than Opthea.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opthea	$87.67K	5,986.77	-$220.24M	N/A	N/A
Harmony Biosciences	$714.73M	2.66	$128.85M	$2.51	13.22

Summary

Harmony Biosciences beats Opthea on 13 of the 17 factors compared between the two stocks.